Published in Medical Letter on the CDC and FDA, December 3rd, 2006
ARRY-797 is a potent, selective, orally active inhibitor of p38 MAP kinase and has demonstrated good tolerability and significant efficacy in preclinical models of human inflammatory diseases. The compound will initially be evaluated in dose escalation studies in normal, healthy volunteers for safety, exposure and inhibition of mechanism-related biomarkers.
"Advancing ARRY-797, our small molecule p38 inhibitor, into clinical trials is a significant achievement...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA